ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time.
Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024
Time: 1:05 p.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$93.50 |
| Daily Change: | -0.68 -0.72 |
| Daily Volume: | 1,286,732 |
| Market Cap: | US$3.140B |
February 27, 2025 February 18, 2025 October 28, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
